{"title":"赖氨酸甲基转移酶SMYD2和SMYD3：肾脏疾病的新靶点。","authors":"Xinyu Du, Liyuan Yao, Shougang Zhuang","doi":"10.1159/000547202","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The SET and MYND domain-containing (SMYD) protein family is a group of lysine methyltransferases with SET and MYND domains and plays a critical role in regulating gene expression through the methylation of histone and non-histone proteins.</p><p><strong>Summary: </strong>Studies have linked mutations or overexpression of SMYD2 and SMYD3 to various cancers, including renal carcinoma. Recent research also demonstrates that the expression levels and activity of SMYD2 and SMYD3 are increased in animal models of renal diseases such as autosomal dominant polycystic kidney disease, renal fibrosis, and diabetic nephropathy. Inhibiting either SMYD2 or SMYD3 pharmacologically or genetically can effectively suppress renal tumorigenesis and cystic formation while improving outcomes in renal fibrosis and diabetic nephropathy. Additionally, SMYD2 and SMYD3 are involved in the pathogenesis of acute kidney injury.</p><p><strong>Key messages: </strong>This review summarizes the roles of these two lysine methyltransferases in renal diseases, highlights their mechanisms, and emphasizes their potential as therapeutic targets for kidney disorders.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"518-529"},"PeriodicalIF":3.1000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334150/pdf/","citationCount":"0","resultStr":"{\"title\":\"Lysine Methyltransferases SMYD2 and SMYD3: Emerging Targets in Kidney Diseases.\",\"authors\":\"Xinyu Du, Liyuan Yao, Shougang Zhuang\",\"doi\":\"10.1159/000547202\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The SET and MYND domain-containing (SMYD) protein family is a group of lysine methyltransferases with SET and MYND domains and plays a critical role in regulating gene expression through the methylation of histone and non-histone proteins.</p><p><strong>Summary: </strong>Studies have linked mutations or overexpression of SMYD2 and SMYD3 to various cancers, including renal carcinoma. Recent research also demonstrates that the expression levels and activity of SMYD2 and SMYD3 are increased in animal models of renal diseases such as autosomal dominant polycystic kidney disease, renal fibrosis, and diabetic nephropathy. Inhibiting either SMYD2 or SMYD3 pharmacologically or genetically can effectively suppress renal tumorigenesis and cystic formation while improving outcomes in renal fibrosis and diabetic nephropathy. Additionally, SMYD2 and SMYD3 are involved in the pathogenesis of acute kidney injury.</p><p><strong>Key messages: </strong>This review summarizes the roles of these two lysine methyltransferases in renal diseases, highlights their mechanisms, and emphasizes their potential as therapeutic targets for kidney disorders.</p>\",\"PeriodicalId\":17830,\"journal\":{\"name\":\"Kidney Diseases\",\"volume\":\"11 1\",\"pages\":\"518-529\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334150/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kidney Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000547202\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547202","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Lysine Methyltransferases SMYD2 and SMYD3: Emerging Targets in Kidney Diseases.
Background: The SET and MYND domain-containing (SMYD) protein family is a group of lysine methyltransferases with SET and MYND domains and plays a critical role in regulating gene expression through the methylation of histone and non-histone proteins.
Summary: Studies have linked mutations or overexpression of SMYD2 and SMYD3 to various cancers, including renal carcinoma. Recent research also demonstrates that the expression levels and activity of SMYD2 and SMYD3 are increased in animal models of renal diseases such as autosomal dominant polycystic kidney disease, renal fibrosis, and diabetic nephropathy. Inhibiting either SMYD2 or SMYD3 pharmacologically or genetically can effectively suppress renal tumorigenesis and cystic formation while improving outcomes in renal fibrosis and diabetic nephropathy. Additionally, SMYD2 and SMYD3 are involved in the pathogenesis of acute kidney injury.
Key messages: This review summarizes the roles of these two lysine methyltransferases in renal diseases, highlights their mechanisms, and emphasizes their potential as therapeutic targets for kidney disorders.
期刊介绍：
''Kidney Diseases'' aims to provide a platform for Asian and Western research to further and support communication and exchange of knowledge. Review articles cover the most recent clinical and basic science relevant to the entire field of nephrological disorders, including glomerular diseases, acute and chronic kidney injury, tubulo-interstitial disease, hypertension and metabolism-related disorders, end-stage renal disease, and genetic kidney disease. Special articles are prepared by two authors, one from East and one from West, which compare genetics, epidemiology, diagnosis methods, and treatment options of a disease.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
